US equities |
AMD $508.50 ▲+5.08% AMZN $270.96 ▲+8.09% AAPL $352.83 ▲+6.31% NVDA $205.47 ▼-0.59% SPCX $137.85 ▼-2.45% TSLA $386.24 ▼-3.08% META $631.60 ▲+1.70% MU $847.56 ▼-0.88%
FinancialContent

Ardelyx, Inc. - Common Stock (NQ:ARDX)

3.285 +0.255 (+8.42%)
Delayed Quote Updated: 9:46 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ARDX CLASS ACTION REMINDER - Robbins LLP Reminds Ardelyx, Inc. Investors of the Pending Lead Plaintiff Deadline in the ARDX Class Action
From Robbins LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
What 6 Analyst Ratings Have To Say About Ardelyx ↗
 
Via Benzinga
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ARDX Lawsuit Reminder - Robbins LLP Encourages Ardelyx, Inc. Stockholders to Seek Counsel for Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
News headline image
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ardelyx and Symbotic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Shareholder Rights Law Firm Robbins LLP Urges ARDX Stockholders with Large Losses to Contact the Firm for Information About the Ardelyx, Inc. Lawsuit
From Robbins LLP
Via Business Wire
News headline image
ARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, Ardelyx, Symbotic, and Five Below and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, Ardelyx, Symbotic, and Five Below and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ARDX Class Action Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardelyx, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
News headline image
ARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ARDELYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Ardelyx, Inc. Investor Notice: Robbins LLP Reminds Shareholders of the Pending ARDX Class Action
From Robbins LLP
Via Business Wire
News headline image
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Stockholder Alert: Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Against ARDX
From Robbins LLP
Via GlobeNewswire
News headline image
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >